Biocept, Inc , a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample.
Biocept is a micro cap stock with a total market cap of 2.57M.
They trade on the NASDAQ and had their IPO 9 years and 4 months
Biocept currently employs 50 people.
News Relating to $BIOC
Proactive Investors
Biocept appoints Antonino Morales as president and chief executive officer
Wednesday Jun 21 2023 at 08:14
Biocept Inc (NASDAQ:BIOC) has announced the appointment of Antonino Morales as its president and chief executive officer, effective immediately. Morales, who has been serving as the company’s interim chief financial officer since February 2022 and as a director of the company since July 2021, will now take on the leadership role.
Business Wire
Biocept to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 20, 2023
Wednesday Jun 14 2023 at 16:05
SAN DIEGO–(BUSINESS WIRE)–Biocept, Inc. (Nasdaq: BIOC) (“Biocept” or the “Company”), a leading provider of molecular diagnostic assays, products and service, announces that management will present at the Maxim Group Virtual Healthcare Conference hosted by M-Vest on Tuesday, June 20 at 9:00 a.m. Eastern time (6:00 a.m. Pacific time). Biocept’s discussion will be hosted by Maxim Group Senior Research Analyst Michael Okunewitch. Registration information to become an M-Vest member for access to t.
Proactive Investors
Biocept says poster presentation at ASCO highlights impressive performance of CNSide assay in detecting leptomeningeal metastases
Monday Jun 05 2023 at 09:36
Biocept Inc (NASDAQ:BIOC) said that a poster presentation at the annual American Society of Clinical Oncology (ASCO) demonstrates the impressive ability of the company’s cerebrospinal fluid assay CNSide to detect rates of leptomeningeal metastases, compared with standard CSF cytology from lumbar puncture. In a nutshell, leptomeningeal metastases (LM), is a type of cancer in the cerebrospinal fluid and membranes that surround a person’s brain and spinal cord (the leptomeninges).
InvestorPlace
Why Is Biocept (BIOC) Stock Down 42% Today?
Thursday May 25 2023 at 08:56
Biocept (NASDAQ: BIOC ) stock is falling hard on Thursday after the company revealed details of a public offering for its shares. Biocept is offering 1,176,470 shares of its common stock and warrants for up to 2,352,940 shares of BIOC stock.
Proactive Investors
Biocept shares to commence trading on split-adjusted basis
Wednesday May 17 2023 at 09:06
Biocept has announced a one-for-thirty reverse stock split which became effective at 4:05pm Eastern Time on May 16, 2023. The company’s common stock will begin trading on a split-adjusted basis as of the open of the market on May 17 under Biocept’s existing ticker symbol “BIOC.
Proactive Investors
Biocept outlines plans to get CNSide assay system commercially available, looks back on the 2022 financial year
Monday Apr 17 2023 at 16:47
Biocept Inc (NASDAQ:BIOC), which develops and commercializes molecular diagnostic assays, revealed new details about its plans to get its CNSide assay system off the ground in 2023. Interim CEO Samuel Riccitelli told shareholders that the company decided that the best course of action is to further develop and commercialize CNSide while pursuing various options to extend its cash runway.
Proactive Investors
Biocept says enrollment begins in FORESEE clinical trial using CNSide to evaluate patients with leptomeningeal metastases
Friday Mar 24 2023 at 09:01
Biocept Inc (NASDAQ:BIOC), a provider of molecular diagnostic assays, products and services, revealed that the first patient with leptomeningeal metastases has been enrolled in the FORESEE clinical trial with the company’s proprietary cerebrospinal fluid assay CNSide (NCT05414123). In a nutshell, leptomeningeal metastases, or LM, is cancer in your cerebrospinal fluid and membranes that surround your brain and spinal cord (the leptomeninges).
Seeking Alpha
Biocept, Inc. (BIOC) Q3 2022 Earnings Call Transcript
Monday Nov 28 2022 at 18:26
Biocept, Inc. (NASDAQ:BIOC ) Q3 2022 Earnings Conference Call November 28, 2022 4:00 PM ET Company Participants Jody Cain – LHA Investor Relations Sam Riccitelli – Chairman and Interim President and Chief Executive Officer Antonino Morales – Interim Chief Financial Officer Conference Call Participants Kemp Dolliver – Brookline Capital Markets Operator Good day, and welcome to the Biocept Third Quarter Financial Results Conference Call. All participants are in a listen-only mode.
Proactive Investors
Biocept reports 176% year-over-year jump in orders for CNSide assay
Monday Nov 21 2022 at 16:53
Biocept Inc (NASDAQ:BIOC) has reported a 176% year-over-year jump in orders for its CNSide product, a cerebrospinal fluid assay addressing unmet needs for patients with central nervous system metastasis. Commenting on its third-quarter results, Biocept CEO Samuel Riccitelli said the company was executing well on its strategy to generate further evidence to secure higher reimbursement for CNSide and support its adoption into clinical care guidelines.
Proactive Investors
Biocept adds CPA Quyen Dao-Haddock to board, bringing extensive financial acumen to audit committee
Friday Nov 18 2022 at 08:59
Biocept Inc (NASDAQ:BIOC) said it has appointed certified public accountant Quyen Dao-Haddock to its board of directors, bringing her more than 20 years of financial and accounting experience to the audit committee. This increases board membership to eight for the San Diego-based provider of molecular diagnostic assays, products and services.
Insider Trading
(Original Source: SEC.GOV)
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Over the last 3 months, there has been no insider trading.
Debt & Income Analysis
(Original Source: SEC.GOV)
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
$BIOC’s Income Quality of 0.51 is in line with its Industry Group of 0.51
$BIOC’s Income Quality of 0.51 is in line with its Major Industry Group of 0.51
$BIOC’s Income Quality of 0.51 is in line with its Sector of 0.51
(Original Source: SEC.GOV)
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
$BIOC’s Current Ratio of 2.97 is in line with its Industry Group of 2.97
$BIOC’s Current Ratio of 2.97 is greater than its Major Industry Group of 1.84 (61.4% greater)
$BIOC’s Current Ratio of 2.97 is greater than its Sector of 1.56 (90.4% greater)
Value Analysis
(Original Source: SEC.GOV)
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Cannot compare a negative PE Ratio (-0.07 & -1.69)
Cannot compare a negative PE Ratio (-0.07 & -0.36)
Cannot compare a negative PE Ratio (-0.07 & -0.32)
(Original Source: SEC.GOV)
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
$BIOC’s PB Ratio of 0.14 is lower than its Industry Group of 1.93 (-92.7% lower)
$BIOC’s PB Ratio of 0.14 is lower than its Major Industry Group of 1.89 (-92.6% lower)
$BIOC’s PB Ratio of 0.14 is lower than its Sector of 1.92 (-92.7% lower)
Efficiency Analysis
(Original Source: SEC.GOV)
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
$BIOC’s ROE of -2.06 is lower than its Industry Group of -0.8 (-157.5% lower)
$BIOC’s ROE of -2.06 is lower than its Major Industry Group of -0.6 (-243.3% lower)
$BIOC’s ROE of -2.06 is lower than its Sector of -0.03 (-6766.7% lower)
(Original Source: SEC.GOV)
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
$BIOC’s ROCE of -1.07 is lower than its Industry Group of -0.71 (-50.7% lower)
$BIOC’s ROCE of -1.07 is lower than its Major Industry Group of -0.55 (-94.5% lower)
Cannot compute a percentage difference when there are zeros in the calculation